ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients.

ERBB2 gene enrichment has an increasing trend in pathological stages I–IV of PAAD and UCEC, while their performance appears to have a decreasing tendency in pathological stages I–IV of KICH and KIRC ( Figure 1E ).

also in 63,971 other papers